Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

122P - Comparison of the efficacy of neoadjuvant pembrolizumab vs sintilimab combination with chemotherapy in resectable lung cancer: A multicenter propensity score matching study


31 Mar 2023


Poster Display session


Xiaolong Yan


Journal of Thoracic Oncology (2023) 18 (4S): S106-S115.


X. Yan1, H. Duan2

Author affiliations

  • 1 Xi'an/CN
  • 2 The Second Affiliate Hospital of Air Force Medical University/Tangdu Hospital, xi'an/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 122P


This study aims to evaluate the effectiveness of using Pembrolizumab or Sintilimab combined with chemotherapy in NSCLC treatment using the Propensity Score Matching (PSM) analysis.


The NSCLC patients were treated with neoadjuvent Pembrolizumab or Sintilimab combined with chemotherapy in two hospitals since June 2018. The objective response rate (ORR), pathological complete response (pCR), and operation-related information of the two groups were analyzed by PSM analysis.


Here, 116 patients were enrolled in the study, where 61 were classified into the Sintilimab group while 55 were included in the Pembrolizumab group. The results indicated that 28 patients (45.9%) in the Sintilimab group achieved pCR while 30 patients (54.5%) in the Pembrolizumab group showed pCR(P = 0.353). No significant differences were noted in MPR between the Sintilimab and Pembrolizumab groups (39, 63.9% vs 36, 65.5%, P = 0.861). Furthermore, the ORR values showed no statistically significant differences between the groups when compared to the assessment of the effects by the Sintilimab and the Pembrolizumab groups (46, 75.4% vs. 44, 80.0%, P = 0.554). There was no discernible difference in ORR and pCR values between the two groups after the first and second PSM analyses. After a Logistic analysis, before and after PSM, treatment with ≥3 cycles were still regarded as the promoting factor of pCR.

Table: 122P
Sintilimab (n = 61)Pembrolizumab(n = 55)P
Smoking Index0.07
Pathological type0.069
Squamous cell cancer45(73.8)48(87.3)
Adenocarcinoma Cycles of neoadjuvant therapy16(26.2)79(12.7)0.002
Clinical stage0.670
I, II14(22.9)11(20.0)
RECIST 1.1 evaluation0.554
Pathlogical evaluation0.353


Sintilimab or Pembrolizumab combined with chemotherapy display a similar pCR to the neoadjuvant treatment of resectable NSCLC. So these both PD-1 inhibitors could show similar effects in NSCLC treatment.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.